CIPREC Centro de Investigación y Prevención Cardiovascular - CABA

Centro de Atención Médica dedicado a la conducción de Estudios de Investigación Clínica en diferentes fases de desarrollo con más de 10 años de experiencia en diversas áreas de especialización.

Av. Pueyrredón 1746 2° A, C1119 Cdad. Autónoma de Buenos Aires, Argentina

Websitehttp://www.ciprec.org/es

Select an option

I am a doctor

I am a sponsor

Specializations

Diabetes

Gastroparesia diabética

Obesidad

Colangitis biliar primaria

Cardiovascular

Enfermedad renal crónica

Hígado graso

Covid-19

Our team

Medical staff

Eliana Serrano

Fernando Guerlloy

Irene Copati

Agustina Bandoni

Agustina Filograsso

Evelyn Garre

Lucia Rey

Vanesa Espinosa

Amanda Gomez

Fernando Guerlloy - C

César Zaidman

Angela Romero Zarante

César Javier Zaidman

Fernando Gruz

Ezequiel Slutsky

Pablo Olivera Sendra

Noelia Broqua

Tania Zarowsky

Mariano Gabriel Marini

Open studies

Obesity

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and Company

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) - ls (ATTAIN-HYPERTENSION - Eli Lilly and Company

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 - ATTAIN-HYPERTENSION - Eli Lilly and Company

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain - TRIUMPH-7 - Eli Lilly and Company

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - Amgen

Breast Cancer

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and Company

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) - CAMBRIA-2 - AstraZeneca

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence - ELEGANT - Stemline Therapeutics, Inc.

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease - FourLight-3 - Pfizer

Arterial hypertension

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) - ls (ATTAIN-HYPERTENSION - Eli Lilly and Company

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 - ATTAIN-HYPERTENSION - Eli Lilly and Company

Hidradenitis suppurativa

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa - RECHARGE 1 - Novartis Pharmaceuticals

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) - Merck Sharp & Dohme LLC

Cardiovascular disease

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and Company

Cholangitis

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis - AFFIRM - Gilead Sciences

Cirrhosis

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis - AFFIRM - Gilead Sciences

Dermatitis

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) - DUPLEX-AD - Janssen Research & Development, LLC

Elevated Lipoprotein A

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and Company

Fatty Liver

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis - Kowa Research Institute, Inc.

Fatty liver/nash

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis - Kowa Research Institute, Inc.

Heart failure

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - Amgen

Low Back Pain

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain - TRIUMPH-7 - Eli Lilly and Company

Renal disease

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and Company

About usOur mission Our team Partners FAQs

Medical newsLatest news Studies Interviews Testimonials

ProductsUEPM Onco UEPM Physicians

LinksDownloads

CIPREC Centro de Investigación y Prevención Cardiovascular - CABA

Av. Pueyrredón 1746 2° A, C1119 Cdad. Autónoma de Buenos Aires, Argentina

Websitehttp://www.ciprec.org/es

Select an option

I am a doctor

I am a sponsor

Specializations

Diabetes

Gastroparesia diabética

Obesidad

Colangitis biliar primaria

Cardiovascular

Enfermedad renal crónica

Hígado graso

Covid-19

Our team

Medical staff

Eliana Serrano

Fernando Guerlloy

Irene Copati

Agustina Bandoni

Agustina Filograsso

Evelyn Garre

Lucia Rey

Vanesa Espinosa

Amanda Gomez

Fernando Guerlloy - C

César Zaidman

Angela Romero Zarante

César Javier Zaidman

Fernando Gruz

Ezequiel Slutsky

Pablo Olivera Sendra

Noelia Broqua

Tania Zarowsky

Mariano Gabriel Marini

Open studies

Obesity

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and Company

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) - ls (ATTAIN-HYPERTENSION - Eli Lilly and Company

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 - ATTAIN-HYPERTENSION - Eli Lilly and Company

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain - TRIUMPH-7 - Eli Lilly and Company

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - Amgen

Breast Cancer

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and Company

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) - CAMBRIA-2 - AstraZeneca

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence - ELEGANT - Stemline Therapeutics, Inc.

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease - FourLight-3 - Pfizer

Arterial hypertension

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) - ls (ATTAIN-HYPERTENSION - Eli Lilly and Company

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 - ATTAIN-HYPERTENSION - Eli Lilly and Company

Hidradenitis suppurativa

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa - RECHARGE 1 - Novartis Pharmaceuticals

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) - Merck Sharp & Dohme LLC

Cardiovascular disease

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and Company

Cholangitis

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis - AFFIRM - Gilead Sciences

Cirrhosis

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis - AFFIRM - Gilead Sciences

Dermatitis

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) - DUPLEX-AD - Janssen Research & Development, LLC

Elevated Lipoprotein A

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and Company

Fatty Liver

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis - Kowa Research Institute, Inc.

Fatty liver/nash

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis - Kowa Research Institute, Inc.

Heart failure

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - Amgen

Low Back Pain

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain - TRIUMPH-7 - Eli Lilly and Company

Renal disease

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and Company

About usOur mission Our team Partners FAQs

Medical newsLatest news Studies Interviews Testimonials

ProductsUEPM Onco UEPM Physicians

LinksDownloads